Intelligence Profile
Clinical Applications
Based on the limited available evidence, TB-500 (Thymosin Beta-4 Fragment) is being investigated for several potential therapeutic applications, though the clinical research remains in early stages.
Current Clinical Investigations
Cardiovascular Applications: One active Phase 1/2 clinical trial (NCT07487363) is currently recruiting participants to evaluate TB-500's effects on cardiovascular biomarkers in patients with stable atherosclerotic cardiovascular disease (ASCVD). This represents the most formal clinical investigation of the compound to date.
Musculoskeletal and Athletic Performance: A 2026 review in Sports Medicine examined TB-500 among other peptide therapies for musculoskeletal injuries and athletic performance enhancement. However, specific efficacy data and clinical outcomes for TB-500 were not detailed in the available evidence.
Research Limitations
The clinical evidence base for TB-500 remains notably limited. While the compound has been characterized chemically as the N-terminal acetylated 17-23 fragment of thymosin beta-4, comprehensive clinical trial data demonstrating safety and efficacy for specific medical conditions is not yet available in the peer-reviewed literature.
The characterization study from 2012 noted that TB-500 was "suspected to possess doping potential," highlighting concerns about its use in competitive athletics and the need for proper regulatory oversight.
Clinical Context
Given the early stage of clinical research, TB-500's therapeutic applications remain largely investigational. The ongoing cardiovascular trial may provide initial insights into the compound's clinical potential, but definitive conclusions about its safety and efficacy for any medical condition cannot be drawn from the current evidence base.
This information is for educational purposes only and does not constitute medical advice. Consult with healthcare professionals for guidance on specific medical conditions.